Çѱ¹À¯¹æ¾ÏÇÐȸ 2022 Ãß°èÇмú´ëȸ : 2022-10-15±³À°ÀÏÀÚ : 2022-10-15
±³À°Àå¼Ò : ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 4Ãþ ÄÁº¥¼ÇȦ
±³À°ÁÖÁ¦ :
2022 Ãß°èÇмú´ëȸÁÖÃÖ±â°ü : Çѱ¹À¯¹æ¾ÏÇÐȸ
´ã´çÀÚ : Á¤Áö¿µ
¿¬¶ôó : 02-3461-6060
À̸ÞÀÏ :
kbcs@kbcs.or.kr ±³À°Á¾·ù : ³»°ú, ¿Ü°ú
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª :
±¤ÁÖ±¤¿ª½Ã±³À°½Ã°£ : 11 ½Ã°£ 40ºÐ
¼¼ºÎ¼ö°·á : 80,000¿ø
ºñ°í Á¤È¸¿ø. ÁØȸ¿ø 60,000¿ø Àü°øÀÇ.°£È£»ç 30,000¿ø ºñȸ¿ø 80,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ A 09:10~09:40 HER2 heterogeneity and HER2-low breast cancer ¿øÇý¼º(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ A 09:40~10:10 Updates of adjuvant/neoadjuvant therapy in HER2+ non-metastatic breast cancer À̽¾Æ(Â÷ÀÇ°úÇдë)
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ A 10:10~10:40 Updates of metastatic HER2+ breast cancer treatment ±ÇÁ¤Çý(Ãæ³²ÀÇ´ë)
ÈÞ½Ä 10-15 10:40~11:00 Break ()
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ A 11:00~11:30 Optimal management and duration in ER-low breast cancer Á¤¼ºÀÇ(°í½ÅÀÇ´ë)
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ A 11:30~12:00 Which CDK 4/6 inhibitor with endocrine therapy in high-risk HR+ breast cancer ¹è¼ö¿¬(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ A 12:00~12:30 Updates of metastatic HR+/HER2- breast cancer treatment ¾ç¿¹¿ø(ÃæºÏÀÇ´ë)
½Ä»ç 10-15 12:30~13:30 ÀÓ½ÃÃÑȸ ¹× LUNCH ()
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ A 13:30~14:00 Potential biomarkers in TNBC ¾È¼º±Í(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ A 14:00~14:30 Updates of adjuvant/neoadjuvant therapy in non-metastatic TNBC ÃÖÁ¤Àº(¿µ³²ÀÇ´ë)
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ A 14:30~15:00 Updates of metastatic TNBC treatment °í¼öÁø(¿ï»êÀÇ´ë)
ÈÞ½Ä 10-15 15:00~15:20 Break ()
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ A 15:20~15:50 Breast cancer screening based on risk assessment: time to update KBCS guidelines? ¹é¼ö¿¬(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ A 15:50~16:15 Adjuvant treatment with bisphosphonates and other bone-modifying agents: updated ASCO guideline in breast cancer ±èÁö¼±(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ A 16:15~16:40 Practically coping with side effects of CDK 4/6 inhibitor and dose adjustment ¹ÚÈñ¼º(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ B 09:10~09:40 De-escalation of breast surgery in patients with predicted pCR after neoadjuvant chemotherapy °û¼ºÂù(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ B 09:40~10:10 Omitting axillary sentinel lymph node biopsy following neoadjuvant chemotherapy À¯Àç¹Î(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ B 10:10~10:40 Optimal regional nodal irradiation following breast surgery in N1 disease À̼±¿µ(ÀüºÏÀÇ´ë)
ÈÞ½Ä 10-15 10:40~11:00 Break ()
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ B 11:00~11:15 À¯¹æ¾Ï ºÐ¾ß¿¡¼ ȯÀÚÁ᫐ Àӻ󿬱¸ÀÇ Çʿ伺 ¹× ÇöȲ Çã´ë¼®(PACEN»ç¾÷´Ü)
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ B 11:15~11:30 ÃÊÀ½ÆÄ°Ë»ç ÈÄ ÀÓ»ó ¸²ÇÁÀý À½¼ºÀÎ À¯¹æ¾ÏȯÀÚ¿¡¼ ¾×¿Í¼ö¼ú »ý·«ÀÇ ¾ÈÀü¼º¿¡ °üÇÑ ÀüÇâÀû, ´Ù±â°ü, 3»ó ÀÓ»ó½ÃÇè ÇÑ¿ø½Ä(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ B 11:30~11:45 ÀþÀº À¯¹æ¾Ï ȯÀÚ¿¡¼ °¡ÀÓ·Â º¸Á¸À» À§ÇÑ ´ÙÇÐÁ¦ °øµ¿ ÀÇ»ç °áÁ¤ ±èÈñÁ¤(¿ï»êÀÇ´ë)
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ B 11:45~12:00 Ãʱâ À¯¹æ¾ÏȯÀÚ¿¡¼ ÃßÀû °üÂû°Ë»ç¹ýÀÇ ÃÖÀûÈ ¿¬±¸ ¹®Çü°ï(¼¿ïÀÇ´ë)
Åä·Ð 10-15 ÄÁº¥¼ÇȦ B 12:00~12:30 Panel discussion: À¯¹æ¾Ï ºÐ¾ß ȯÀÚÁ᫐ Àӻ󿬱¸ÀÇ °³¼± ¹× ¹ßÀü¹æÇâ ±è¹ÎÁ¤¿Ü4ÀÎ(PACEN ¿Ü)
½Ä»ç 10-15 12:30~13:30 ÀÓ½ÃÃÑȸ ¹× LUNCH ()
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ B 13:30~14:00 Application of 3D printing technique in breast surgery °í¹ü¼®(¿ï»êÀÇ´ë)
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ B 14:00~14:30 ICG-hyaluronic acid injection for non-palpable breast lesion localization ½ÅÇõÀç(ÇѾçÀÇ´ë)
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ B 14:30~15:00 Surgical experiences in breast disease management ±è¿¹Á¤(ÀüÁÖ¿¹¼öº´¿ø)
ÈÞ½Ä 10-15 15:00~15:20 Break ()
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ B 15:20~15:40 Neoadjuvant chemotherapy Á¤ÀçÇÐ(À»ÁöÀÇ´ë)
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ B 15:40~16:00 Surgical treatment ¹ÎÁØ¿ø(´Ü±¹ÀÇ´ë)
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ B 16:00~16:20 Metastatic breast cancer °»óÀ²(ÀüºÏÀÇ´ë)
Åä·Ð 10-15 ÄÁº¥¼ÇȦ B 16:20~16:40 Panel discussion ¹Ú¿µ»ï¿Ü2ÀÎ(ÀüÁÖ¿¹¼öº´¿ø ¿Ü)